Kawamura, Yusuke

Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update

Kudo, M., Kawamura, Y., Hasegawa, K., Tateishi, R., Kariyama, K., Shiina, S., Toyoda, H., Imai, Y., Hiraoka, A., Ikeda, M., et al. (2021) · Liver Cancer

Hepatocellular Carcinoma Treatment and PrognosisHead and Neck Cancer Studies

Cited by 678

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Qin, S., Chen, M., Cheng, A.-L., Kaseb, A. O., Kudo, M., Lee, H. C., Yopp, A. C., Zhou, J., Wang, L., Wen, X., et al. (2023) · The Lancet

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 545

Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma

Kawamura, Y., Arase, Y., Ikeda, K., Seko, Y., Imai, N., Hosaka, T., Kobayashi, M., Saitoh, S., Sezaki, H., Akuta, N., et al. (2012) · American Journal of Gastroenterology

Liver Disease Diagnosis and TreatmentHepatocellular Carcinoma Treatment and Prognosis

Cited by 280

SGLT2 inhibitor treatment outcome in nonalcoholic fatty liver disease complicated with diabetes mellitus: the long-term effects on clinical features and liver histopathology

Akuta, N., Kawamura, Y., Fujiyama, S., Sezaki, H., Hosaka, T., Kobayashi, M., Kobayashi, M., Saitoh, S., Suzuki, F., Suzuki, Y., et al. (2020) · Internal Medicine

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 48